- Home
- VACH vs OABI Comparison
VACH vs OABI Comparison
Compare VACH & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VACH
- OABI
- Stock Information
- Founded
- VACH 2023
- OABI 2012
- Country
- VACH United States
- OABI United States
- Employees
- VACH N/A
- OABI N/A
- Industry
- VACH
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- VACH
- OABI Health Care
- Exchange
- VACH NYSE
- OABI Nasdaq
- Market Cap
- VACH 321.3M
- OABI 307.4M
- IPO Year
- VACH 2024
- OABI N/A
- Fundamental
- Price
- VACH $10.20
- OABI $2.28
- Analyst Decision
- VACH
- OABI Strong Buy
- Analyst Count
- VACH 0
- OABI 3
- Target Price
- VACH N/A
- OABI $7.00
- AVG Volume (30 Days)
- VACH 2.0K
- OABI 780.2K
- Earning Date
- VACH 01-01-0001
- OABI 03-18-2025
- Dividend Yield
- VACH N/A
- OABI N/A
- EPS Growth
- VACH N/A
- OABI N/A
- EPS
- VACH 0.26
- OABI N/A
- Revenue
- VACH N/A
- OABI $26,391,000.00
- Revenue This Year
- VACH N/A
- OABI $77.72
- Revenue Next Year
- VACH N/A
- OABI $30.95
- P/E Ratio
- VACH $39.68
- OABI N/A
- Revenue Growth
- VACH N/A
- OABI N/A
- 52 Week Low
- VACH $9.97
- OABI $2.23
- 52 Week High
- VACH $10.25
- OABI $5.54
- Technical
- Relative Strength Index (RSI)
- VACH N/A
- OABI 27.98
- Support Level
- VACH N/A
- OABI $2.38
- Resistance Level
- VACH N/A
- OABI $2.57
- Average True Range (ATR)
- VACH 0.00
- OABI 0.18
- MACD
- VACH 0.00
- OABI -0.04
- Stochastic Oscillator
- VACH 0.00
- OABI 4.42
About VACH VOYAGER ACQUISITION CORP.
Voyager Acquisition Corp is a blank check company.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.